The recent FDA warning regarding BCMA- and CD19-targeted CAR-T cell therapies highlights significant concerns about the potential risk of secondary cancers. However, the research team led by Zhi Dai and Xiaodong Luo has developed a novel natural tumor-specific T-cell therapy that does not rely on lentiviruses or antigen-presenting cells, thereby presenting a safer alternative. This innovative method involves the use of MHC-positive cancer cells and naive T cells to generate specific T cells, which can subsequently be isolated and expanded from peripheral blood. Preclinical studies have demonstrated that this treatment significantly reduces tumor nodules and enhances survival rates in murine models. This breakthrough has the potential to revolutionize the field by offering a safe therapeutic option beyond current adoptive cell transfer (ACT) treatments such as CAR-T, TCR-T, TIL, LAK, and CIK, and is likely to attract interest from researchers across various disciplines for further investigation into tumor antigens and immune mechanisms.

https://link.springer.com/article/10.1007/s13659-024-00472-w

Read More: Natural Products and Bioprospecting

(Editor:YANG Mei)